Israel approves patent application for universal flu vaccine
The approval, which came from the Israeli Intellectual Property Office, applies to the MultiMeric MultiEpitope Polypeptide Influenza Vaccine (M-001) and related polypeptides. The company has already gained patent protection in several European nations and Australia, China, Hong Kong, Japan, Korea, Mexico, Russia and the United States.
The vaccine, part of the company’s larger patent group, is an effort to provide broad protection against influenza strains. The researchers want to make a series of vaccines that will give long-lasting protection. The company aims for the vaccine to be effective against multi-strain, multi-season, seasonal, and pandemic influenza strains.
"We are very pleased that the Israeli patent authorities accepted the uniqueness of our universal flu vaccine solution, approving this main patent of BiondVax,” CEO Ron Babecoff said. “Our solution is patent-protected in many of the countries where we believe our vaccine will provide increased protection to the local population from flu."